PSVT involves episodes of a faster-than-normal heart rate, often with symptoms resembling anxiety attacks, and while uncomfortable, it’s typically not life threatening. Diagnosis of PSVT typically ...
The investigational intranasal L-type calcium channel blocker etripamil continues to be well tolerated and effective for self-treating recurrent episodes of paroxysmal supraventricular tachycardia ...
Cardamyst is now FDA approved as a self-administered intranasal treatment for acute episodes of paroxysmal supraventricular tachycardia.
CARDAMYST nasal spray is a novel and rapid-acting calcium channel blocker delivered when needed to treat often highly symptomatic and unpredictable episodes of PSVT. With CARDAMYST, adults with PSVT ...
A nasal spray that delivers a short-acting calcium-channel blocker (CCB), envisioned as a self-treatment alternative to a pill-in-the-pocket strategy for managing bouts of paroxysmal supraventricular ...
MONTREAL and CHARLOTTE, N.C., June 16, 2025 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) today announced submission of its response to the U.S. Food and Drug Administration (FDA ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved a rapid-acting nasal spray for the treatment of acute symptomatic paroxysmal supraventricular ...
What Is Cardamyst, and Why Does It Matter? Cardamyst (etripamil) is a new nasal spray for treating sudden episodes of fast heartbeats, known as paroxysmal supraventricular tachycardia (PSVT), and ...
(RTTNews) - Milestone Pharmaceuticals Inc. (MIST), a clinical-stage biopharmaceutical company focused on cardiovascular medicines, announced Monday positive results from Phase 3 RAPID clinical trial ...
Hosted on MSN
Milestone Pharmaceuticals shares rally after FDA greenlights first at-home PSVT nasal therapy
Milestone Pharmaceuticals (NASDAQ:MIST) shares jumped roughly 35% after the U.S. Food and Drug Administration approved CARDAMYST, the first nasal spray that patients can self-administer to treat ...
First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel nasal spray designed to rapidly resolve episodes of PSVT and restore sinus rhythm FDA approval in PSVT ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results